Search Results

CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma.

• Authors : Vahidian, Fatemeh^1,2 (AUTHOR) ; Lamaze, Fabien C.¹ (AUTHOR) ; Bouffard, Cédrik^1,2 (AUTHOR)

• Source: Cancers. Feb2024, Vol. 16 Issue 4, p708. 13p.

Record details

Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer.

• Authors : Franzén, Alexander Sebastian^1,2 (AUTHOR); Boulifa, Abdelhadi^1,2 (AUTHOR); Radecke, Clarissa² (AUTHOR)

• Source: Cancers. Jan2024, Vol. 16 Issue 2, p388. 20p.

Record details

Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.

• Authors : Guo, Jia^1,2 ; Yang, Qi^1,2 ; Jiang, Qi¹

Subjects: *THERAPEUTIC use of antineoplastic agents; *NASOPHARYNX cancer; *PROGRAMMED cell death 1 receptors

• Source: Nutrients. Oct2023, Vol. 15 Issue 19, p4262. 19p.

Record details

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.

• Authors : Zhou, Xiang¹ (AUTHOR); Hu, Yongquan² (AUTHOR); Sun, Hong³ (AUTHOR)

• Source: European Journal of Nuclear Medicine & Molecular Imaging. Aug2023, Vol. 50 Issue 10, p3107-3115. 9p. 2 Color Photographs, 7 Charts, 2 Graphs.

Record details

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study.

• Authors : Xie, Jingyuan¹ (AUTHOR); Chen, Mo² (AUTHOR); Han, Hedong¹ (AUTHOR)

• Source: Thoracic Cancer. May2023, Vol. 14 Issue 15, p1327-1338. 12p.

Record details

Camrelizumab for cancers in patients living with HIV: one-single center experience.

• Authors : Wu, Menghua^1,2 (AUTHOR); Zheng, Xin¹ (AUTHOR); Zhang, Yu¹ (AUTHOR)

• Source: AIDS Research & Therapy. 4/16/2023, Vol. 20 Issue 1, p1-7. 7p.

Record details

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond.

• Authors : Fazel, Mina^1,2 (AUTHOR); Dufresne, Armelle¹ (AUTHOR); Vanacker, Hélène^1,2 (AUTHOR)

• Source: Cancers. Mar2023, Vol. 15 Issue 6, p1643. 14p.

Record details

Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas.

• Authors : Sánchez-Canteli, Mario^1,2 (AUTHOR) ; Juesas, Luis¹ (AUTHOR); Garmendia, Irati^2,3 (AUTHOR)

Subjects: *SQUAMOUS cell carcinoma; *PROGRAMMED cell death 1 receptors; *PROGNOSIS

• Source: International Journal of Molecular Sciences. Oct2022, Vol. 23 Issue 19, p11559. 11p.

Record details

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

• Authors : Qu, Jingjing^1,2 (AUTHOR); Kalyani, Farhin Shaheed¹ (AUTHOR); Shen, Qian^1,2 (AUTHOR)

• Source: Journal of Oncology. 9/26/2022, p1-12. 12p.

Record details

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer.

• Authors : Kang, Da Hyun¹ (AUTHOR); Choi, Seong‐woo¹ (AUTHOR); Sun, Pureum² (AUTHOR)

• Source: Thoracic Cancer. Aug2022, Vol. 13 Issue 16, p2346-2354. 9p.

Record details